Fig 1.
Study design: This paper presents the results of Assessment II (boxed in red).
*Rheumatologist was blinded during the two PsA assessments to the PURE-4 results. **15 patients did not attend the second visit to the rheumatologist. PsA, psoriatic arthritis.
Table 1.
Baseline clinical and sociodemographic characteristics of evaluable psoriasis patients who attended Assessment II (variables collected in Assessment I).
Fig 2.
Baseline treatment of patients undergoing psoriasis treatment included in Assessment II.
PDE-4, phosphodiesterase 4; PsA, psoriatic arthritis.
Fig 3.
Flowchart of study population (Assessment I and Assessment II).
*Rheumatologist was blinded during the two PsA assessments to the PURE-4 results. **15 patients did not attend the second visit to the rheumatologist. PsA, psoriatic arthritis.
Table 2.
Results of PURE-4 questionnaire in Assessment II.
Fig 4.
Results of PURE-4 questionnaire by item in Assessment II.
n, number of patients; PsA, psoriatic arthritis.
Fig 5.
Area under ROC curve in Assessment II.
AUC, area under the curve; ROC, receiver-operating characteristic; Se, sensitivity; Sp, specificity.
Table 3.
Sensitivity and specificity results for Assessment II.